NewsLocal News


FDA approves drug as RSV prevention for babies, toddlers

RSV Drug
Posted at 11:16 PM, Jul 17, 2023
and last updated 2023-07-18 08:56:12-04

Doctors will soon have a new tool to prevent respiratory syncytial virus (RSV) hospitalizations in healthy infants and toddlers.

The U.S. Food and Drug Administration (FDA) on Monday approved a drug, Beyfortus, for the prevention of RSV infections.

RSV is a lower respiratory tract infection that causes cold-like symptoms. However, the virus can lead to more serious illnesses similar to pneumonia.

The Centers for Disease Control and Prevention (CDC) says RSV kills between 100 and 300 infants each year. A surge in cases last fall put a strain on Colorado hospitals.

RSV 010920

Local News

CDPHE monitoring 'sharp increase' in RSV hospitalizations, outbreaks

Sydney Isenberg
7:46 PM, Oct 28, 2022

Beyfortus, which was developed by AstraZeneca, is a monoclonal antibody that mimics the immune system's ability to fight off the virus. It is administered in single injection before RSV season and is approved for infants up to 24 months old.

The drug was roughly 78% effective in preventing RSV hospitalizations in clinical trials.

GSK Laboratory

Local News

FDA approves world's first RSV vaccine for older adults

Jessica Porter
10:39 PM, May 03, 2023

Possible side effects of Beyfortus include rash and injection site reactions, according to the FDA.

The drug will be available this fall. There are still questions about how much Beyfortus will cost and if it will be covered under insurance.

D7 follow up bar 2460x400FINAL.png
The Follow Up
What do you want Denver7 to follow up on? Is there a story, topic or issue you want us to revisit? Let us know with the contact form below.